US 11,981,920 B2
Modified cell with enhanced migration capability
Chengfei Pu, Shanghai (CN); Zhiyuan Cao, Shanghai (CN); Lei Xiao, Shanghai (CN); and He Sun, Shanghai (CN)
Assigned to Innovative Cellular Therapeutics Holdings, Ltd., George Town (KY)
Filed by Innovative Cellular Therapeutics Co., Ltd., Shanghai (CN)
Filed on Dec. 3, 2019, as Appl. No. 16/701,917.
Claims priority of provisional application 62/775,168, filed on Dec. 4, 2018.
Prior Publication US 2020/0172865 A1, Jun. 4, 2020
Int. Cl. C12N 5/0783 (2010.01); A61K 35/17 (2015.01); C07K 14/705 (2006.01); C07K 14/725 (2006.01); C07K 16/30 (2006.01); C12N 15/86 (2006.01)
CPC C12N 5/0636 (2013.01) [A61K 35/17 (2013.01); C07K 14/7051 (2013.01); C07K 14/70521 (2013.01); C07K 14/70578 (2013.01); C07K 16/30 (2013.01); C12N 15/86 (2013.01); C07K 2319/02 (2013.01); C07K 2319/03 (2013.01); C12N 2510/00 (2013.01); C12N 2740/15043 (2013.01)] 15 Claims
 
1. A modified T cell comprising a polynucleotide encoding SEQ ID NO: 45, and wherein expression and/or function of CDC42 in the modified T cell has been enhanced.